Navigation Links
How the brain learns to become addicted

Researchers have identified a key signaling molecule in the brain that appears to trigger the brain to "learn" a craving for cocaine. Their finding could offer an important target for drugs to treat addiction by short-circuiting that adaptive process.

In an article in the February 16, 2006, issue of Neuron, Antonello Bonci and colleagues established that a short protein, or peptide, called orexin A acts on a brain region central to the adaptation to addictive drugs. Specifically, they found in their studies with rats that orexin A induces an adaptation that is necessary for the development of behaviors associated with drug-craving in human addicts. The latest findings follow an earlier discovery by the same group that another molecule, corticotropin releasing factor (CRF), acts similarly.

Such adaptations are believed to create a need that is far more compelling than the simple memory of drug-induced pleasure and represent a "rewiring" of the brain into an addictive state.

In a preview article on the paper in the same issue of Neuron, NIH neuroscientist Roy Wise commented that "Inasmuch as arousal or stress can trigger drug-seeking in drug-free animals, the neuroadaptations discovered by the Bonci group are important not only for how rewarding the drug is after an animal starts taking it, but, perhaps more importantly, for how likely the animal is to initiate drug-seeking during periods of abstinence.

"Because it is during periods of abstinence, not periods of intoxication, that addicts seek treatment, the peptide signaling pathways for orexin and CRF may prove to be fruitful targets in the search for addiction medications."

Bonci and his colleagues based their experiments on past studies by other researchers showing that orexins are important regulatory peptides released by a brain center called the lateral hypothalamus. It was also known that orexins tend to activate circuitry in a region called the ventral tegmental area (VT A), known to be a critical site of neural adaptation, or plasticity, induced by addictive drugs. However, it wasn't known whether orexin actually induced such plasticity.

In experiments with rat brain slices, the researchers demonstrated that orexin A does increase activity of neurons in the VTA associated with such plasticity.

And in experiments with whole animals, the researchers found that orexin A was required for "behavioral sensitization" to cocaine. This sensitization shows itself as a long-lasting increase in activity by the animals when they receive the drug and is an indicator that the animals are experiencing an increased craving for the drug.

Importantly, when the researchers "microinjected" directly into the VTA region of animals a drug that blocks orexin receptors, they found they could block the development of behavioral sensitization.

"The findings presented here establish a potential mechanism for the role of orexin signaling in plasticity related to addiction," concluded the researchers. The researchers wrote that this orexin-induced plasticity in the VTA "is likely an important substrate of behaviors relevant to addiction, as we show that activation of [orexin] receptors in the VTA is necessary for the development of cocaine-mediated behavioral sensitization. Thus, orexin receptors may provide novel pharmacotherapeutic targets for motivational disorders such as addiction.


'"/>

Source:Cell Press


Related biology news :

1. Controversial drug shown to act on brain protein to cut alcohol use
2. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
3. Mouse brain tumors mimic those in human genetic disorder
4. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
5. First atlas of key brain genes could speed research on cancer, neurological diseases
6. NYU study reveals how brains immune system fights viral encephalitis
7. Stem cells from brain transformed to produce insulin at Stanford
8. Birds brains reveal source of songs
9. Loves all in the brain: fMRI study shows strong, lateralized reward, not sex, drive
10. Revolutionary nanotechnology illuminates brain cells at work
11. A puzzle piece found in unraveling the wiring of the brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
Breaking Biology Technology: